Liver Failure

• 

  Subject Areas on Research

  • A prognostic model for patients with end-stage liver disease. 
  • A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. 
  • A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1-dependent mechanism. 
  • Abnormal fatty acid metabolism in spinal muscular atrophy may predispose to perioperative risks. 
  • Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiologic study. 
  • Bile acids in xenogeneic ex-vivo liver perfusion: function of xenoperfused livers and compatibility with human bile salts and porcine livers. 
  • Caspase 8 small interfering RNA prevents acute liver failure in mice. 
  • Class II alloantibody and mortality in simultaneous liver-kidney transplantation. 
  • Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. 
  • Death and liver transplantation within 2 years of onset of drug-induced liver injury. 
  • Death of a living liver donor from illicit drugs. 
  • Defining long-term outcomes with living donor liver transplantation in North America. 
  • Depressive symptoms and mortality in lung transplant. 
  • Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. 
  • Developmental Morphogens & Recovery from Alcoholic Liver Disease. 
  • Disparities in liver transplantation before and after introduction of the MELD score. 
  • Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index. 
  • Effect of surgical and spontaneous portasystemic shunts on liver transplantation. 
  • Effects of smoking on survival for patients with end-stage liver disease. 
  • Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. 
  • Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. 
  • Fulminant hepatic failure due to disseminated adenovirus infection in a patient with chronic lymphocytic leukemia. 
  • Fulminant hepatic failure due to herpes simplex after hysteroscopy. 
  • Helicobacter canis bacteremia in a patient with fever of unknown origin. 
  • Hepatic failure after rectal acetaminophen. 
  • Hepatitis C. 
  • Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues. 
  • Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. 
  • Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5. 
  • Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). 
  • Improvement in survival associated with adult-to-adult living donor liver transplantation. 
  • Improvement of multiple sclerosis on tacrolimus plus mycophenolate mofetil after liver transplantation. Clinical improvement of multiple sclerosis in a patient requiring liver transplantation for acute liver failure following interferon-beta therapy. 
  • In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. 
  • Isolated liver transplantation in infants with end-stage liver disease associated with short bowel syndrome. 
  • Isolated liver transplantation in infants with end-stage liver disease due to short bowel syndrome. 
  • Isolated liver transplantation in infants with total parenteral nutrition-associated end-stage liver disease. 
  • Kinetics of hepatitis C virus reinfection after liver transplantation. 
  • Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. 
  • Liver and intestine transplantation in the United States, 1997-2006. 
  • Liver and small bowel transplantation: therapeutic alternatives for the treatment of liver disease and intestinal failure. 
  • Liver transplantation as definitive therapy for complications after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia. 
  • Liver transplantation for Wilson's disease: a single-center experience. 
  • Liver transplantation for alcoholic liver disease. 
  • Liver transplantation from a cadaver donor with ethylene-glycol-induced brain death. 
  • Model for End-Stage Liver Disease score predicts mortality in critically ill cirrhotic patients. 
  • Model for end-stage liver disease (MELD) exception for cholangiocarcinoma or biliary dysplasia. 
  • One Size Does Not Fit All--Regional Variation in the Impact of the Share 35 Liver Allocation Policy. 
  • Portal vein arterialization for the treatment of post resection acute liver failure in the rat. 
  • Portal vein arterialization in hepatobiliary surgery and liver transplantation. 
  • Portal vein oxygen supply through a liver extracorporeal device to treat acute liver failure in Swine induced by subtotal hepatectomy: preliminary data. 
  • Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization. 
  • Postpartum hemorrhage: when uterotonics and sutures fail. 
  • Predictive indices of morbidity and mortality after liver resection. 
  • Pretransplant predictors of recovery of renal function after liver transplantation. 
  • Pretransplant status and patient survival following liver transplantation. 
  • Racial and socioeconomic disparities in pediatric and young adult liver transplant outcomes. 
  • Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. 
  • Rescue of a living donor with liver transplantation. 
  • Reversible nefazodone-induced liver failure. 
  • Reversible retinal edema in an infant with neonatal hemochromatosis and liver failure. 
  • Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. 
  • Successful treatment of CCL4-induced acute liver failure with portal vein arterialization in the rat. 
  • Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. 
  • Survival after adult liver transplantation does not correlate with transplant center case volume in the MELD era. 
  • Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. 
  • Technical aspects of portal vein arterialization for acute liver failure: from rat lab to man. 
  • The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. 
  • The clinical relevance of alloantibody in liver transplantation. 
  • The coagulation cascade in cirrhosis. 
  • The humoral immune response in humans following cross-perfusion of porcine organs. 
  • The role of liver transplantation in the management of portal hypertension. 
  • The spectrum of complications following left ventricular assist device placement. 
  • Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. 
  • Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension. 
  • Use of remifentanil in infants. 
  • Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. 
  • Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients.